Skip to content
HeyJared

Salong Debbarma

Reporter

Indexed articles, last 90 days
82
Latest publication
Sep 23, 2026
Outlet visibility, for yahoo.com
Top 1K sites
Earliest in this view
Jul 6, 2026

Latest articles

  1. Article · Sep 23, 2026 · Salong Debbarma

    BoomRay and Novartis sign $900m deal for radioligand therapy (opens the original)

    Excerpt · Positive tone · English

    Read excerpt

    China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m. The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The partnership combines BoomRay's development experience in RLTs and Novartis's glob

  2. Article · Sep 22, 2026 · Salong Debbarma

    Bounty Oil & Gas agrees deal for Liberia deepwater block (opens the original)

    Excerpt · English

    Read excerpt

    Australia-based Bounty Oil & Gas has agreed to acquire PetroQuest Liberia Deep Water, gaining access to negotiations for a production sharing contract (PSC) covering Block LB-32 offshore Liberia. PetroQuest holds a letter of engagement from the National Oil Company of Liberia, giving it the exclusive right to negotiate a contract with the Liberia Petroleum Regulatory Authority. Block LB-32 is not currently covered by a granted licence or an executed PSC. The proposed acquisition is subject to co

  3. Article · Sep 17, 2026 · Salong Debbarma

    DNO raises Capricorn takeover offer to $396m cash deal (opens the original)

    Excerpt · English

    Read excerpt

    Norwegian oil company DNO has agreed to revised terms for its proposed takeover of UK-listed Capricorn Energy, increasing the offer to $5.214 in cash for each share and valuing the company at $396m (£294m). Capricorn's directors intend to unanimously recommend that shareholders support the deal. The revised proposal replaces an earlier structure that offered $4.224 in cash per share plus a proposed special dividend of $0.99. Under the new terms, shareholders will receive the full acquisition val

  4. Article · Sep 15, 2026 · Salong Debbarma

    Santos agrees LNG arrangements with POSCO and Ksi Lisims (opens the original)

    Excerpt · English

    Read excerpt

    Santos has agreed to two separate non-binding liquefied natural gas (LNG) arrangements covering supply to POSCO Steel and purchases from the proposed Ksi Lisims LNG project in Canada. The agreements support the Australian energy major's strategy of expanding and managing its global LNG portfolio, with supply expected to begin from 2030 or 2031. Under proposed terms with POSCO, Santos would provide LNG for ten years on a 'delivered ex ship' basis. The gas would come from Santos' global LNG portfo

  5. Article · Sep 15, 2026 · Salong Debbarma

    Cheplapharm to take over 20 medicines and three sites from Sanofi (opens the original)

    Excerpt · Neutral tone · English

    Read excerpt

    Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi. Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014. The selected medicines, including Lovenox/Clexane (enoxaparin), are intended to benefit from Cheplapharm's operational approach. The companies stated t

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 1K sites

For yahoo.com, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Salong Debbarma